Evommune shares tumble 13% after-hours after eczema pill trial fails
Evommune (EVMN) shares fell 13% after-hours Tuesday after the company said its experimental eczema pill failed a mid-stage study and will not move forward in that disease.
Shares of Evommune (EVMN) fell 13% after-hours on Tuesday after the company said its experimental eczema pill failed a mid-stage study and will not move forward in that disease. Palo Alto investors had been waiting for the readout as a second chance for EVO756, an oral drug that had already failed in atopic dermatitis.